New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
November 26, 2014
13:50 EDTNBSNeoStem to host a KOL event
Chairman & CEO Smith and CMO Losordo host a Key Opinion Leader Event with the Director of Cardiology at Cedars-Sinai Heart Institute, Dr. Timothy Henry, who discusses the significance of the Phase 2 PreSERVE AMI clinical trial in a meeting being held on December 1 at 4:30 pm. Webcast Link
10:43 EDTPFEMylan calls active after called 'most likely' Pfizer takeover target
Subscribe for More Information
10:34 EDTPFEMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
07:48 EDTPFEMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
November 25, 2014
14:22 EDTLHLabCorp price target raised to $130 from $113 at Craig-Hallum
Subscribe for More Information
November 24, 2014
15:32 EDTLLYEli Lilly reports 9.1% passive stake in Coherus Biosciences
Subscribe for More Information
13:15 EDTNBSNeoStem mentioned positively at Maxim
Subscribe for More Information
07:46 EDTPFEPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 21, 2014
15:26 EDTNBSNeoStem provides info on the design of the Phase 2 PreSERVE AMI trial
Subscribe for More Information
09:17 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTLHLabCorp completes acquisition of LipoScience
Subscribe for More Information
08:03 EDTCYTXCytori Therapeutics announces results in Cytori Cell Therapy trial
Cytori Therapeuticsreported positive results from a clinical study of Cytori Cell Therapy in anterior cruciate ligament reconstruction of patients with ACL tears. The 6 month results from the first 20 patients with combination Cytori Cell Therapy and bone-patellar tendon-bone grafts were presented at the Barcelona Knee Symposium on November 20, 2014. Dr. Ramon Cugat, co-director of the Orthopedic Institute, Hospital Quiron Barcelona and the lead investigator of the study, performed autologous bone-patellar tendon-bone transplantation to replace damaged ACLs in 20 athletes who had sustained injury. Cytori Cell Therapy utilizing adipose derived regenerative cells prepared by the Celution System from a patientís own fat was used with the BPTB graft during the transplantation procedure. The cell preparation, injection into the graft and transplantation of the graft were all performed in the same surgical procedure. Dr. Cugat discussed the preliminary six month outcomes at the meeting. The procedure was feasible and not associated with safety issues above that seen with a standard small volume liposuction. All patients recovered without any complications. The results were compared to a historical control group of patients who had the same surgical procedure by the same surgical team but without other interventions. Overall, recovery from pain and ability to return to the field appeared to be accelerated as a result of the ADRC enriched BPTB transplant The patient questionnaires and serial MRI scans of the knees following cell therapy were consistent with accelerated healing of the graft.
November 20, 2014
09:32 EDTLHLipoScience to host special shareholder meeting
Subscribe for More Information
November 19, 2014
07:52 EDTPFEInforma Business Information to hold a conference
Subscribe for More Information
07:09 EDTNBSJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
11:04 EDTCYTXCytori Therapeutics announces early results from ADVANCE trial
Subscribe for More Information
10:57 EDTSTEMStemCells to host analyst day
Subscribe for More Information
09:20 EDTNBSOn The Fly: Pre-market Movers
Subscribe for More Information
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:29 EDTPFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:20 EDTNBSNeoStem volatility elevated into presenting data
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
07:09 EDTNBSNeoStem to host conference call
Subscribe for More Information
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
18:32 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTNBSNeoStem announces initial positive data from Phase 2 PreSERVE AMI clinical trial
NeoStem announced initial positive data from its 161 patient Phase 2 PreSERVE AMI,or acute myocardial infarction, clinical trial. These data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events, SAEs, and major adverse cardiac events, MACE."For cardiologists, our key goal is to keep patients from progressing to worsening heart muscle function and death after a major heart attack," said Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator of the PreSERVE AMI study. "It is encouraging to see clinically meaningful results this early in the study, and I look forward to future data readouts."
16:04 EDTLLYEli Lilly says empagliflozin tablets reduced A1C, body weight and abdominal fat
Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers of abdominal fat in adults with type 2 diabetes, according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company at the 2014 Scientific Sessions of the American Heart Association in Chicago. Abdominal fat, also known as visceral fat, sits on or near vital organs. The study presented at AHA included analyses of two sets of adults with T2D treated with either empagliflozin or placebo. The first group consisted of 823 adults with high blood pressure who were treated for 12 weeks, while the second examined a pool of 2,476 adults from four different trials who were treated for 24 weeks. These randomized studies compared empagliflozin with placebo as an add-on to existing therapy, including metformin, metformin plus sulfonylurea, or pioglitazone with or without metformin. In both groups, treatment with empagliflozin significantly reduced A1C, body weight and several markers of abdominal fat compared with placebo. Changes in estimated total body fat did not reach statistical significance.
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
11:11 EDTNBSHigh option volume stocks:
Subscribe for More Information
11:06 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use